At the systemic level, metformin suppresses insulin/IGF-1 and nuclear factor-κB (NF-κB) signaling pathways, downregulates the release of proinflammatory cytokines and augments CD8+ T cell anti-tumor responses [8]. This evidence concerns the gene INS and neoplasm.